


Organizer



HELLENIC ONCOLOGICAL
SOCIETY OF DIASPORA

Scientific Program



3rd WEBINAR

Minimal Residual Disease

DECEMBER 14th, 2022

18.30-20.30 GR Time | 17.30 -19.30 CET


Secretariat



Scientific | Cultural Events & Publications

www.scep.gr





Welcome Letter

Dear Colleagues, Dear Friends,

The concept of minimal residual disease (MRD) has revolutionized the way we understand cancer recurrence and treatment resistance. MRD has been used to describe the small number of residual disseminated tumor cells, which evade treatment giving rise to metastases. A growing number of studies have verified the clinical value of MRD as a predictive indicator for disease recurrence and overall survival, serving as a useful marker of systemic disease. The foremost advantage of MRD is that it reflects more accurately cancer spatial and temporal heterogeneity and, thus, allows tracking of the metastatic burden.

In this context, liquid biopsy approaches enable MRD monitoring, thereby contributing towards the identification of those who face a higher risk of disease relapse. However, many technical issues remain in MRD detection and monitoring, especially in solid tumor patients. Isolation of circulating tumor cells (CTCs) or other factors that cancer cells extrude into the bloodstream, such as circulating tumor DNA (ctDNA), remains a challenging laboratory problem. Since 2016, ctDNA-based techniques have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the identification and quantification of somatic epidermal growth factor receptor (EGFR) mutations that allows us to pinpoint patients with NSCLC who will benefit from targeted therapies, specifically in cases where we are not able to obtain a tissue biopsy. The unavailability of tissue samples for molecular profiling is a common problem in daily clinical practice and, thus, taking into account that tumor sampling is invasive, costly, and time consuming, non-invasive methods for MRD assessment represent an important paradigm shift in precision medicine.

On behalf of Hellenic Oncological Society of Diaspora (HeL.O.DI), we kindly invite you to attend the webinar entitled “**Minimal Residual Disease (MRD)**”, which will be held on **December 14th, 2022**. This webinar will cover all the aforementioned issues presenting the most recent advances by experts in the field.


With warm regards,

F.I. Dimitrakopoulos (GR)

MD, PhD, Medical Oncologist,
Division of Oncology & Molecular Oncology,
Laboratory, Department of Medicine,
University of Patras, Greece

D. Papadatos - Pastos (UK)

MRCP(UK), PhD, Consultant in Medical Oncology,
Lung Cancer and Acute Oncology,
University College London Hospitals and
The Princess Alexandra Hospital, UK



Wednesday, December 14th, 2022

18.30-20.30 GR Time | 17.30 -19.30 CET

Moderators: **D. Papadatos - Pastos (UK)**, **F.I. Dimitrakopoulos (GR)**

18.30-18.50 GR Time 17.30-17.50 CET	Liquid Biopsy as a tool for the detection of minimal residual disease Q&A	E. Lianidou (GR)
18.55-19.15 GR Time 17.55-18.15 CET	Circulating Tumor DNA and Minimal Residual Disease in Early-Stage Colorectal Cancer Q&A	M. Giannakis (US)
19.20-19.40 GR Time 18.20-18.40 CET	MRD in oncology. The right technology for the right data Q&A	N. Tsoulos (GR)
19.45-20.05 GR Time 18.45-19.05 CET	The emerging value of liquid biopsy for the monitoring of MRD in NSCLC Q&A	P. Christopoulos (DE)
20.10-20.30 GR Time 19.10-19.30 CET	The importance of liquid biopsy for monitoring of oncogene driven non small cell lung cancer Q&A	A. Dimou (US)

Faculty

F.I. Dimitrakopoulos | MD, PhD, Medical Oncologist, Division of Oncology & Molecular Oncology, Laboratory, Department of Medicine, University of Patras, Greece

A. Dimou | MD, Senior Associate Consultant, Division of Medical Oncology, Assistant Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA


P. Christopoulos | Professor of Medicine at Heidelberg University, MD, PhD, Hematologist & Medical Oncologist in the Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Germany

M. Giannakis | MD, PhD, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute. Assistant Professor of Medicine, Harvard Medical School, Boston, USA

E. Lianidou | PhD Professor of Analytical Chemistry - Clinical Chemistry Analysis of Circulating Tumor Cells (ACTC) Lab Dept of Chemistry, University of Athens, Greece

D. Papadatos - Pastos | MRCP(UK), PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, UK

N. Tsoulos | MSc, MBA, PhDc, Molecular Biochemist, CEO Genekor Medical SA, Greece



3rd WEBINAR
Minimal Residual Disease
DECEMBER 14th, 2022

Info

Organized by



HELLENIC ONCOLOGICAL
SOCIETY OF DIASPORA

Date

December 14th, 2022

Official Language

The official language of the Webinar is English

Participation to the Meeting

There will be a live streaming connection through a special platform. We would like to inform you that you can attend the webinar as a participant by following the Link and the instructions in the corresponding field below.

To attend the event you are interested in please visit www.livetime.gr and follow the steps below:

1. Proceed with your registration on the page www.livetime.gr (registration on the platform is required only upon your first visit, to attend subsequent conferences and events you only have to login using your username / email and password that you have set).
2. Select the event you wish to attend
3. Click on the button "Event Registration"

Certificate of Attendance


The certificate of attendance will be given to the participants at the end of the Webinar via the platform www.livetime.gr

Secretariat



Scientific | Cultural Events & Publications

T +30 210 7240039 www.sccp.gr



3rd WEBINAR
Minimal Residual Disease
DECEMBER 14th, 2022

Sponsors



Genekor

Committed to Biotechnological Innovation



Secretariat



Scientific | Cultural Events & Publications

www.scep.gr

